Main menu

TATAA Biocenter GrandPeformance Assays

Jun 15, 2017

TATAA Biocenter has launched GrandPerformance assays for expression profiling single circulating tumor cells. The assays' workflow is based on preamplification allowing precise measurements of 96 specific expression markers per cell. They are also optimized for single-cell sensitivity.

More Like This

Thermo Fisher Scientific has launched PureLink Fast Low-Endotoxin Plasmid Purification Medi and Maxi kits. The new kits allow researchers to isolate transfection-quality plasmid DNA in about 30 minutes, yielding 0.4 milligrams with the midi version and 1.5 milligrams with the maxi version.

Sep 26, 2017

DiaSorin Molecular Pneumocystis Jirovecii Primer Pair

DiaSorin Molecular has introduced a Pneumocystis jirovecii primer pair for use in laboratory-developed molecular tests. This analyte-specific reagent can be used for the amplification and detection of the Pneumocystis jirovecii mtLSU gene with a CFR610- and BHQ-2-labeled probe and forward and reverse primers. This is DiaSorin's first fungal infectious disease target, and the new primer pair adds to the company's menu of more than 60 molecular reagents for the detection of bacterial and viral targets, and human genetic mutations.

Sep 25, 2017

Interpace MVPdX Lung Cancer Test

Interpace Diagnostics has launched a new lung cancer test, MVPdX, that compares the mutational fingerprint of two or more sites of lung cancer to differentiate new primary lung tumors from recurrences or metastases. The assay is based on an analysis of loss of heterozygosity via a panel of microsatellite markers in proximity to 16 tumor suppressor genes.

Sep 21, 2017

PierianDx Clinical Genomicist Workspace

PierianDx said that its Clinical Genomicist Workspace genomics workflow and analysis software now supports clinical microarray technology (CMA). CMA enhancements within CGW include workflow integration to submit processed microarray results from a batch of samples to generation of a templated report without user intervention; the ability to review, sort, and filter copy number variants (CNV) as well as loss of heterozygosity (LOH) segments and associated quality information; the ability to set laboratory-specific validation filters for CNV and LOH segments as well as specific panel- and case-specific filters; clinical interpretations that are automatically inferred in patient cases for review and editing; and an updated knowledgebase that includes published literature for articles that mention cytogenetic positions, genes, and phenotypes associated with a patient case.

Sep 20, 2017

Blueprint Genetics Whole Exome Sequencing

Blueprint Genetics is now offering whole-exome sequencing to customers in the US. The assay has a minimum mean coverage of 100-fold. On average, 98.9 percent of gene-coding regions, captured with Agilent SureSelect V6, are covered at least 15-fold. The company confirms all clinically relevant variants by Sanger sequencing and its interpretation team includes clinical experts. Turnaround time for the assay, which comes in different versions, is six to nine weeks.

Sep 19, 2017

ARUP Laboratories/IDbyDNA Explify Respiratory

ARUP Laboratories and IDbyDNA have launched Explify Respiratory, a next-generation sequencing-based test for respiratory infections. Explify Respiratory detects more than 200 common and rare bacterial, fungal, and viral respiratory pathogens with a single test. It is powered by IDbyDNA's Taxonomer software, a DNA search engine that can rapidly identify any organism by its genetic material. The test is the first in a line of tests that ARUP Labs and IDbyDNA plan to launch as part of a previously announced strategic partnership to develop and commercialize infectious disease testing using metagenomics.

Sep 18, 2017

Horizon Discovery CRISPRi and CRISPRa Screening Services

Horizon Discovery announced that it has expanded its functional genomic screening portfolio to include CRISPRi (interference) and CRISPRa (activation) screening services. Horizon's CRISPRi/CRISPRa screening platform substantially broadens the range of possible studies through the capacity to reduce or increase, rather than completely eliminating gene expression, the company said. This enables customers to address critical gaps in target ID and validation as they work to develop novel and more effective drug therapies. The screening capabilities are based on the company's highly optimised CRISPR knockout screening platform. Horizon has also developed an enhanced solution that combines both CRISPRi and CRISPRa screening. This combined solution can reveal 'switch'-like genes that display opposing effects when activated or inhibited in the presence of the drug of interest.

Sep 18, 2017

Evosep One

Evosep introduced Evosep One, an optimized separation technology for mass spectrometers for large cohort experiments. Evosep One is designed for fast and robust separation of omics samples while enabling 24-hour operation at 200 samples a day. The product reduces cross-contamination through the use of disposable tips, and high flow rate during autosampler washing steps. According to the company, Evosep One also improves up time and reliability through partial elution that leaves impurities from each sample on the disposable tips that act as pre-columns, and from low-pressure elution and gradient formation that causes less wear and tear.

Sep 14, 2017

Qnostics ME Evaluation Panel

Qnostics launched the ME Evaluation Panel for meningitis/encephalitis evaluation. It consists of 14 controls for the qualitative detection of bacterial, viral, and fungal targets, including Neisseria meningitidis, Haemophilus influenzae, Escherichia coli K1, and others. The panel can be used to independently monitor each target and all phases of the testing process, Qnostics said, adding it was designed with known performance on the BioFire FilmArray platform.

BC Platforms BC|RQUEST

BC Platforms has introduced BC|RQUEST, a system for analyzing and viewing aggregated genomic and clinical data from multiple biobanks. The platform will be available to members of the Open Biobank Research Enhancement Alliance (OBREA), which Basel, Switzerland-based BC Platforms created.

DiaSorin Molecular Simplexa C. difficile Direct Assay

DiaSorin Molecular has launched the Simplexa C. difficile Direct Assay in the US. The assay aids in the diagnosis of infection by detecting the C. difficile toxin B gene in liquid or unformed stool samples, and had been available outside the US since November. The US Food and Drug Administration cleared the test in February.

Sep 12, 2017

Benson Hill Biosystems CRISPR 3.0

Benson Hill Biosystems has launched CRISPR 3.0, a novel family of Cms1 nucleases, as part of its suite of genomics tools to accelerate crop performance improvements. The CRISPR 3.0 portfolio of nucleases demonstrate a shorter length than many other widely-used nucleases, enabling easier delivery, the firm said.

Sep 12, 2017

Bio-Rad ZDC Multiplex RT-PCR assay

Bio-Rad Laboratories has launched the ZDC Multiplex RT-PCR assay, a research-use only tool for the simultaneous screening of sample for Zika, dengue, and chikungunya arbovirus RNAs. The assay comes with all controls that researchers need to validate results internally. The RT-PCR kit was launched outside the US earlier this year.